Weight Loss Induced by Chronic Dapagliflozin Treatment Is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

(2010) E. Ferrannini et al.   DIABETES CARE

The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats

(2010) F. R. Macdonald et al.   DIABETES OBESITY & METABOLISM

Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight

(2010) L. Zhang et al.   DIABETES OBESITY & METABOLISM

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET

Glucose Control by the Kidney: An Emerging Target in Diabetes

(2009) Olivera Marsenic   AMERICAN JOURNAL OF KIDNEY DISEASES

Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

(2009) B Komoroski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

(2009) B Komoroski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats

(2009) Yoshikazu Fujimori et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-Ay mice

(2009) Kenji Katsuno et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Molecular physiology of weight regulation in mice and humans

(2009) R L Leibel   INTERNATIONAL JOURNAL OF OBESITY

Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats

(2008) S. Han et al.   DIABETES

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

(2008) J. F. List et al.   DIABETES CARE

Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

(2008) Wei Meng et al.   JOURNAL OF MEDICINAL CHEMISTRY